UK’s NICE Backs Interim Funding For 14-Day Ambulatory Heart Monitoring Tech
Health technology assessment body says that while iRhythm Technologies’ Zio XT service improves cardiac arrhythmia detection, more data must be collected to address evidence gaps about its benefit.
You may also be interested in...
With health care in the UK being increasingly restructured around digital delivery, bodies like the new NHSX, NHS Digital and the forthcoming Digital Innovation Hubs will be in the forefront of health-care policy-making at the national level. A new government funding pledge has underlined the importance of taking the opportunities that artificial intelligence, machine learning and genomic medicine offer in health care.
Results from a study of more than 91,000 ECG records collected with iRhythm’s Zio ambulatory continuous cardiac monitoring device that demonstrates the successful application of artificial intelligence to ECGs gives the 12-year-old company confidence that it will be profitable very soon.
Health technology assessment body NICE wants Kite to collect more evidence to prove that Tecartus can cure relapsed or refractory mantle cell lymphoma. But in the meantime, it says the CAR-T therapy should be made available on the National Health Service, making UK patients among the first in the world to be offered access to the treatment.